Oz Management is a privately-owned hedge fund manager that also offers alternative asset management services to clients across the globe. The firm provides its management services to different entities, including corporations, funds, collateralized loan obligations, and more. Oz Management recently submitted its SEC 13F filings for the period ended September 30, 2014. The filings showed that Actavis PLC (NYSE:ACT), AbbVie Inc (NYSE:ABBV), and Allergan, Inc. (NYSE:AGN) were the biggest holdings of the firm for the quarter.
The biggest investment of Oz Management was Actavis PLC (NYSE:ACT), coming out with investment worth $1.2 billion. Actavis PLC (NYSE:ACT) is a specialty pharmaceutical company that develops, manufactures, and sells high quality generic and branded biosimilar and pharmaceutical products. Analysts at Citigroup have recently given the stock a “buy” rating and have gone ahead to increase the target price to $310 from the $250 it had initially given the stock. Actavis PLC (NYSE:ACT) has experienced growth to feature among the top 10 pharmaceutical companies by market value.
AbbVie Inc (NYSE:ABBV) was the second largest investment with a value of $885.6 million. AbbVie Inc (NYSE:ABBV) is a research based pharmaceutical company with its headquarters in North Chicago, Illinois. The company focuses on specialty therapeutic areas such as chronic kidney disease, immunology, women’s health, and more. Two Hepatitis C drugs developed by AbbVie Inc (NYSE:ABBV) have received the nod of European regulators for the treatment of the disease, which is a known cause of need for liver transplants. The two new generation drugs are Dasabuvir and Viekirax.
The third biggest investment of Oz Management was Allergan, Inc. (NYSE:AGN), accounting for a total investment value of $692.9 million. Allergan, Inc. (NYSE:AGN) is a pharmaceuticals company that focuses on ophthalmic pharmaceuticals, dermatology, neuroscience, urology and cosmetics. The company develops and sells pharmaceuticals, biologics, medical devices, and more. The top three shareholders of Allergan, Inc. (NYSE:AGN) are Pershing Square Capital Management, L.P., Biovail Corp, and T. Rowe Price Associates, Inc.
This article has been written by Victor Ochieng.
